Clinicopathologic characteristics and outcome of patients with different EGFR mutations-Reference-Cited by-同舟云学术

Clinicopathologic characteristics and outcome of patients with different EGFR mutations

Published:2018-10-11 Issue:3 Volume:15 Page:166-171
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Zhou Shengyu¹,Hu Xingsheng¹,Wang Yan¹,Li Junling¹,Zhou Liqiang¹,Hao Xuezhi¹,Liu Yutao¹,Shi Yuankai¹^ORCID

Affiliation:

1. Department of Medical OncologyNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China

Funder

Chinese National Major Project for New Drug Innovation

CAMS Innovation Fund for Medical Sciences

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13072

Reference35 articles.

1. Cancer statistics, 2017

2. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

3. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

4. Epidermal growth factor receptor mutations in lung cancer

5. Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18;Translational Lung Cancer Research;2024-04

2. Heterogeneous distribution of EGFR mutation in NSCLC: Case report;Respiratory Medicine Case Reports;2023

3. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes;Cancer Epidemiology;2022-02

4. Correlation of Epidermal Growth Factor Receptor Mutation With Major Histologic Subtype of Lung Adenocarcinoma According to IASLC/ATS/ERS Classification;Cancer Control;2022-01

5. How specific molecular‑targeted agents can make obsolete a ‘one size fits all’ approach in EGFR‑mutated NSCLC treatment (Review);Experimental and Therapeutic Medicine;2021-08-10